Skip to main content

Table 2 Changes in various parameters between baseline and 12 weeks after trelagliptin therapy

From: Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study

  Baseline After 12 weeks P value
FMD (%), mean (SD) 2.42 (2.7) 2.66 (3.8) 0.785
Adiponectin (μg/mL), mean (SD) 7.72 (6.9) 8.82 (8.3) 0.002
ADMA (μM/L), mean (SD) 0.41 (0.0) 0.40 (0.0) 0.402
BMI (kg/m2), mean (SD) 24.6 (3.2) 24.4 (3.0) 0.219
Body weight (kg), mean (SD) 64.9 (8.9) 64.5 (9.5) 0.266
HbA1c (%), mean (SD) 7.5 (1.0) 7.1 (0.9) 0.051
Fasting plasma glucose, mean (SD) 145.8 (35.9) 129.1 (36.4) 0.033
IRI (μU/mL), mean (SD) 14.3 (10.1) 14.5 (10.6) 0.913
HOMA index, mean (SD) 5.0 (4.0) 4.5 (4.2) 0.469
β-cell function, mean (SD) 69.0 (48.7) 88.3 (74.3) 0.193
eGFR (mL/min/1.73 m2), mean (SD) 82.7 (21.1) 79.8 (22.3) 0.062
ACR (mg/gCr), mean (SD) 39.7 (62.3) 34.7 (53.6) 0.244
Systolic blood pressure (mmHg), mean (SD) 129.8 (8.0) 129.9 (9.6) 0.945
Diastolic blood pressure (mmHg), mean (SD) 79.7 (7.3) 77.6 (8.8) 0.240
LDLC (mg/dL), mean (SD) 120.5 (31.4) 110.4 (28.7) 0.001
HDLC (mg/dL) mean (SD) 53.2 (14.0) 52.9 (12.9) 0.745
TG (mg/dL), mean (SD) 134.3 (49.4) 132.6 (54.5) 0.871
Mean CIMT (mm), mean (SD) 1.76 (1.3) 1.42 (0.5) 0.227
Mean ba-PWV (cm/s), mean (SD) 1633 (244.1) 1569 (217.1) 0.045
  1. SD standard deviation, FMD flow-mediated dilatation, ADMA asymmetric dimethyl arginine, BMI body mass index, eGFR estimated glomerular filtration rate, ACR albumin creatinine ratio, HbA1c hemoglobin A1c, LDLC low-density lipoprotein cholesterol, HDLC high-density lipoprotein cholesterol, TG triglyceride, IRI immunoreactive insulin, HOMA homeostasis model assessment, CIMT carotid intima media thickness, ba-PWV brachial ankle pulse wave velocity